FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has further expanded its European business of Visually Directed High Intensity Focused Ultrasound (“HIFU”) using the Sonablate® 500 for prostate cancer treatment with entry into Portugal. The Sonablate 500 (“SB500”) is a medical device developed by Focus Surgery, Inc. and manufactured by Misonix. Misonix also has the exclusive European distribution rights for the product. Misonix is an investor in privately-held Focus Surgery, one of the most prominent developers of HIFU in the world.
